1-20 of 29
Keri Maher
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Global, Phase 3, Randomized, Double-Blind Study to Evaluate Safety and Efficacy of Selinexor, an XPO-1 Inhibitor, in Combination with Ruxolitinib in JAK Inhibitor-Naïve Myelofibrosis (XPORT-MF-034)

Keri Maher, Raajit K. Rampal, Prithviraj Bose, Nikolai A. Podoltsev, Claire N Harrison, Junshik Hong, Xulong Wang, Kamal Chamoun, John Mascarenhas
Journal: Blood
Blood (2023) 142 (Supplement 1): 3209.
https://doi.org/10.1182/blood-2023-180695
Published: 2023
Journal Articles

Phase 1b/2 Study of Escalating Doses of the NEDD8 Activating Enzyme Inhibitor Pevonedistat Administered in Combination with Standard Induction Therapy (Cytarabine and Idarubicin) in Newly Diagnosed High Risk Acute Myeloid Leukemia

Carissa M. Feliciano, Jennifer S. Carew, Hetty E. Carraway, Justin M. Watts, Sharad Khurana, Bhumika J. Patel, Keri Maher, Claudia Espitia, Kaijin Wu, Denice Tsao-Wie, Xuelian Chen, Mikkael A. Sekeres, Stan Louie, Homa Dadrastoussi, Eduardo Fernandez, Julian Olea, Brandon Sookdeo, Steffan T. Nawrocki, George Yaghmour, Kevin R. Kelly
Journal: Blood
Blood (2023) 142 (Supplement 1): 4279.
https://doi.org/10.1182/blood-2023-185481
Published: 2023
Journal Articles

Clinical Significance of Clonal Evolution: A Comparison of Relapsed Versus Refractory Acute Myeloid Leukemia

Graeme Murray, Ian Bouligny, Thuy Ho, Juhi Gor, Keri Maher
Journal: Blood
Blood (2023) 142 (Supplement 1): 4310.
https://doi.org/10.1182/blood-2023-185146
Published: 2023
Journal Articles

CPX-351 Versus FLAG-IDA with or without Venetoclax in Previously Untreated and Relapsed or Refractory Acute Myeloid Leukemia

Ian Bouligny, Graeme Murray, Thuy Ho, Juhi Gor, Kyle Zacholski, Nolan Wages, Steven Grant, Keri Maher
Journal: Blood
Blood (2023) 142 (Supplement 1): 4269.
https://doi.org/10.1182/blood-2023-189184
Published: 2023
Journal Articles

Recent Advancements in Acute Myeloid Leukemia Have Led to Incremental Improvement in Overall Survival

Thuy Ho, Graeme Murray, Juhi Gor, Ian Bouligny, Keri Maher
Journal: Blood
Blood (2023) 142 (Supplement 1): 5187.
https://doi.org/10.1182/blood-2023-183022
Published: 2023
Journal Articles

Revisiting Ratify: Daunorubicin 60 Mg/m 2 Vs 90 Mg/m 2 in Previously Untreated FLT3 mut Acute Myeloid Leukemia

Ian Bouligny, Graeme Murray, Thuy Ho, Juhi Gor, Kyle Zacholski, Nolan Wages, Steven Grant, Keri Maher
Journal: Blood
Blood (2023) 142 (Supplement 1): 5912.
https://doi.org/10.1182/blood-2023-189138
Published: 2023
Journal Articles

Toward a Measurable Residual Disease-Based Algorithm for Selection of Allogeneic Hematopoietic Stem Cell Transplant in Acute Myeloid Leukemia

Thuy Ho, Juhi Gor, Ian Bouligny, Graeme Murray, Keri Maher
Journal: Blood
Blood (2023) 142 (Supplement 1): 7090.
https://doi.org/10.1182/blood-2023-182190
Published: 2023
Journal Articles

Validation of the Charlson Comorbidity Index Model in Acute Myeloid Leukemia Treated with a Hypomethylating Agent and Venetoclax

Ian Bouligny, Graeme Murray, Thuy Ho, Juhi Gor, Kyle Zacholski, Nolan Wages, Steven Grant, Keri Maher
Journal: Blood
Blood (2023) 142 (Supplement 1): 5093.
https://doi.org/10.1182/blood-2023-189322
Published: 2023
Journal Articles

Safety, Pharmacodynamic, and Anti-Tumor Activity of SL-172154 As Monotherapy and in Combination with Azacitidine (AZA) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Patients (pts)

Naval Daver, Anthony Selwyn Stein, Dale Bixby, Wanxing Chai-Ho, Joshua F. Zeidner, Keri Maher, Don A. Stevens, Maximilian Stahl, Karen Yee, Emily K Curran, Sawa Ito, Andrew Sochacki, David A Sallman, Robert Hernandez, Simon Metenou, Bo Ma, Kazunobu Kato, Amer M. Zeidan
Journal: Blood
Blood (2023) 142 (Supplement 1): 4278.
https://doi.org/10.1182/blood-2023-173991
Published: 2023
Journal Articles

CUX1 mut Acute Myeloid Leukemia As a Distinct Biological Entity: An Analysis of Clinical Outcomes and Implications

Ian Bouligny, Graeme Murray, Thuy Ho, Juhi Gor, Kyle Zacholski, Nolan Wages, Steven Grant, Keri Maher
Journal: Blood
Blood (2023) 142 (Supplement 1): 5978.
https://doi.org/10.1182/blood-2023-189407
Published: 2023
Journal Articles

Selinexor Plus Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Patients with Myelofibrosis: Long Term Follow up from XPORT-MF-034 Suggestive of Disease Modification

Srinivas K. Tantravahi, Ashwin Kishtagari, Keri Maher, Sanjay Mohan, Josef T. Prchal, Xulong Wang, Kamal Chamoun, Christopher J Walker, Pietro Taverna, Haris Ali
Journal: Blood
Blood (2023) 142 (Supplement 1): 622.
https://doi.org/10.1182/blood-2023-180844
Published: 2023
Journal Articles

Impact of Recent Advancements in Relapsed/Refractory Acute Myeloid Leukemia on Overall Survival in Clinical Practice

Thuy Ho, Juhi Gor, Graeme Murray, Ian Bouligny, Keri Maher
Journal: Blood
Blood (2023) 142 (Supplement 1): 1474.
https://doi.org/10.1182/blood-2023-185132
Published: 2023
Journal Articles

First-Line Venetoclax and a Hypomethylating Agent or Conventional Chemotherapy in Older Adults with IDH -Mutated AML

Ian Bouligny, Graeme Murray, Thuy Ho, Juhi Gor, Kyle Zacholski, Nolan Wages, Steven Grant, Keri Maher
Journal: Blood
Blood (2023) 142 (Supplement 1): 1488.
https://doi.org/10.1182/blood-2023-188400
Published: 2023
Journal Articles

Impact of COVID-19 Pandemic on Overall Survival in Acute Myeloid Leukemia: A Comprehensive Cancer Center Experience of 627 Patients

Juhi Gor, Ian Bouligny, Thuy Ho, Graeme Murray, Keri Maher
Journal: Blood
Blood (2023) 142 (Supplement 1): 7437.
https://doi.org/10.1182/blood-2023-190759
Published: 2023
Journal Articles

Comprehensive Molecular Stratification of Patients with AML Treated with CPX-351

Thuy Ho, Juhi Gor, Graeme Murray, Ian Bouligny, Keri Maher
Journal: Blood
Blood (2023) 142 (Supplement 1): 6006.
https://doi.org/10.1182/blood-2023-187655
Published: 2023
Journal Articles

Comparison of Response and Survival with Chemotherapy and Targeted Therapies between IDH mut Isoforms in Acute Myeloid Leukemia

Ian Bouligny, Graeme Murray, Thuy Ho, Juhi Gor, Kyle Zacholski, Nolan Wages, Steven Grant, Keri Maher
Journal: Blood
Blood (2023) 142 (Supplement 1): 6010.
https://doi.org/10.1182/blood-2023-188362
Published: 2023
Journal Articles

The Impact of Delayed Venetoclax Initiation on Overall Survival in Acute Myeloid Leukemia

Ian Bouligny, Graeme Murray, Thuy Ho, Juhi Gor, Kyle Zacholski, Nolan Wages, Steven Grant, Keri Maher
Journal: Blood
Blood (2023) 142 (Supplement 1): 4233.
https://doi.org/10.1182/blood-2023-188249
Published: 2023
Journal Articles

FLT3 Inhibitors in Combination with FLAG-IDA in Relapsed or Refractory Acute Myeloid Leukemia

Ian Bouligny, Graeme Murray, Thuy Ho, Juhi Gor, Kyle Zacholski, Nolan Wages, Steven Grant, Keri Maher
Journal: Blood
Blood (2023) 142 (Supplement 1): 5920.
https://doi.org/10.1182/blood-2023-188333
Published: 2023
Journal Articles

The Molecular Landscape of Acute Myeloid Leukemia with Trisomy 8: A Comprehensive Cancer Center Analysis of 627 Patients

Ian Bouligny, Graeme Murray, Thuy Ho, Juhi Gor, Kyle Zacholski, Nolan Wages, Steven Grant, Keri Maher
Journal: Blood
Blood (2023) 142 (Supplement 1): 6053.
https://doi.org/10.1182/blood-2023-189260
Published: 2023
Journal Articles

Real-World (RW) Evaluation of Acute Myeloid Leukemia (AML) Induction Therapies in the Community Setting: A Retrospective Evaluation of Outcomes of Intensive Chemotherapy, Venetoclax-Based Regimens, and Non-IC-Based Treatments

Keri Maher, Cherrishe Brown-Bickerstaff, Ali McBride, Ajeet Gajra, Djibril Liassou, Ying Qiu, Marné Garretson, JaLyna Laney, David Huggar, David Hughes
Journal: Blood
Blood (2022) 140 (Supplement 1): 13278–13279.
https://doi.org/10.1182/blood-2022-169762
Published: 2022